Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Pfeffer, Marc
Item TypeName
Academic Article Role of the fibrinolytic system in preventing myocardial infarction.
Academic Article Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Academic Article Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Academic Article Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Academic Article The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Academic Article Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Academic Article Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Academic Article Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Academic Article Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Academic Article Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Academic Article Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction.
Academic Article Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Academic Article Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Academic Article Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Academic Article Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
Academic Article Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Academic Article Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Academic Article Altered vascular responsiveness: initial hypotensive mechanism of thiazide diuretics. 1.
Academic Article Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
Academic Article Systemic hemodynamic effects of endothelin in rats.
Academic Article Role of angiotensin II in the altered renal function of heart failure.
Academic Article Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Academic Article Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Academic Article Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Academic Article Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Academic Article Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
Academic Article Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Academic Article Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.
Academic Article Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Academic Article Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Academic Article Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Academic Article Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
Academic Article Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Academic Article Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Academic Article Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.
Academic Article Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Academic Article Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Academic Article Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Academic Article Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
Academic Article Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Academic Article Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Academic Article Dual renin-angiotensin system blockade in heart failure.
Academic Article Albuminuria in chronic heart failure: prevalence and prognostic importance.
Academic Article Dual renin-angiotensin system blockade and kidney disease.
Academic Article Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Academic Article Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Academic Article Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Academic Article Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Academic Article AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.
Academic Article Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Academic Article Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Academic Article High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Academic Article Mechanism of the negative inotropic action of leukotrienes C4 and D4 on isolated rat heart.
Academic Article Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Academic Article Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Academic Article Role of angiotensin II in the altered renal function of congestive heart failure.
Academic Article The CHARM program: study design leads to findings of clinical and public health importance.
Academic Article Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Academic Article Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Academic Article Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Academic Article Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Concept Angiotensin II
Concept Angiotensin II Type 1 Receptor Blockers
Academic Article Irbesartan in patients with atrial fibrillation.
Academic Article Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
Academic Article Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Academic Article International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Academic Article Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Academic Article Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
Academic Article Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
Academic Article Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Academic Article Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Academic Article Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Academic Article Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Academic Article Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Search Criteria
  • Angiotensin II
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.